(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 56.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Ocular Therapeutix's revenue in 2026 is $55,783,000.On average, 15 Wall Street analysts forecast OCUL's revenue for 2026 to be $13,329,315,086, with the lowest OCUL revenue forecast at $10,919,535,130, and the highest OCUL revenue forecast at $16,285,348,760. On average, 10 Wall Street analysts forecast OCUL's revenue for 2027 to be $23,967,840,600, with the lowest OCUL revenue forecast at $11,504,137,393, and the highest OCUL revenue forecast at $65,320,354,915.
In 2028, OCUL is forecast to generate $48,029,422,088 in revenue, with the lowest revenue forecast at $20,481,957,863 and the highest revenue forecast at $77,726,109,210.